Puma May Face Marketing Hurdles Even If Neratinib Wins Final Approval

Neratinib's value as extended adjuvant therapy for HER2-positive breast cancer may be diminished if Roche succeeds in altering the standard of care for initial adjuvant treatment, among other challenges.